Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

Native name	第一三共株式会社
Romanized name	Daiichi Sankyō kabushiki gaisha
Type	Public KK
Traded as	TYO: 4568 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component
Industry	Pharmaceutical
Predecessors	Daiichi Pharmaceutical Company Sankyo Company
Founded	Tokyo, Japan (2005 (2005)) (by merger)
Headquarters	Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan
Key people	Sunao Manabe (Representative Director, and President) Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
Products	Medical equipment Pharmaceutical products Veterinary medicines
Revenue	$ 9.028 billion USD (FY 2019) (¥ 981.8 billion JPY) (FY 2019)
Net income	$ 1.276 billion USD (FY 2019) (¥ 138.8 billion JPY) (FY 2019)
Number of employees	15,348 (as of March 2020)
Website	http://www.daiichisankyo.com
Footnotes / references

Daiichi Sankyo Company, a Tokyo-based global pharmaceutical leader, operates across various sectors of the medical industry, providing an extensive portfolio of treatments for a wide range of conditions.

In the cancer domain, they offer innovative treatments like trastuzumab deruxtecan, gefitinib, bicalutamide, and tamoxifen. They also provide drugs for pain management, neurological disorders, such as Alzheimer's, and epilepsy.

Their diabetes and heart disease portfolio includes products like teneligliptin, canagliflozin, pravastatin, and edoxaban, while their gastrointestinal and infectious disease lineups offer treatments like esomeprazole and vaccines for various conditions.

Daiichi Sankyo also contributes to the skincare and oral care sectors with products such as Transino and Breath Labo. Their range even extends to over-the-counter medicines, animal healthcare products, cosmetics, medical equipment, and food products.

In a partnership with Guardant Health, they are developing a companion diagnostic for a lung cancer treatment. Founded in 1899, Daiichi Sankyo's legacy of innovation continues to shape the global pharmaceutical landscape.

Macro Analysis

The global macroeconomic environment has a significant influence on the performance of Daiichi Sankyo and the pharmaceutical industry as a whole. The recent inflation print shows that the annual inflation rate has dropped to 3% from 4% the previous month, settling into an acceptable range. This is a positive sign for companies like Daiichi Sankyo as it reduces the cost pressure on raw materials and other inputs.

The S&P 500 gained 2.4% and the NASDAQ jumped 3.3%, indicating a positive market sentiment which could benefit the company. However, the tightening of interest rates, with the US 10-year moving from 4.06% to 3.83%, could increase the cost of borrowing for the company.

Industry Overview

Daiichi Sankyo operates in the pharmaceutical industry, which is characterized by high levels of research and development, stringent regulatory environments, and intense competition. The industry is driven by innovation, with companies constantly seeking to develop new treatments and therapies. The industry has been positively impacted by the COVID-19 pandemic, with increased focus on healthcare and accelerated vaccine development.

Competitor Comparison

Daiichi Sankyo's main competitors in the pharmaceutical industry include global giants like Eli Lilly, Johnson & Johnson, Novo Nordisk, Merck & Co., Roche Holding, Abbvie, Novartis, Astrazeneca, Pfizer, and Sanofi. These companies have a broad product portfolio and significant resources for research and development.

Company Overview and Breakdown

Daiichi Sankyo Co., Ltd. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The company is involved in the research, development, manufacture, and sale of pharmaceuticals, over-the-counter drugs, and vaccines. It also provides administrative services such as human resources and accounting services, real estate leasing, and insurance agency business.

Financials

Daiichi Sankyo has shown strong financial performance with revenues increasing by 22% to 1.278 trillion yen and net income increasing by 63% to 108.95 billion yen for the fiscal year ended 31 March 2023. The company's current ratio is 2.8, indicating a strong liquidity position. The company's debt ratio is 9.7, which is relatively low, indicating a manageable level of debt.

The company's return on assets (ROA) is 4.6% and return on equity (ROE) is 7.8%, indicating efficient use of assets and equity. The company's gross margin is 71.6% and net profit margin is 8.5%, indicating strong profitability.

Cash flow statement
Cash flows from operating activities
Profit for the year

Valuation

The company's current price-to-earnings (P/E) ratio is 69.15, which is relatively high, indicating that the company's stock may be overvalued. The company's price-to-book (P/B) ratio is 5.21, which is also relatively high.

Technical Analysis

The company's stock price has shown some volatility, with a 1-year return of 11.47%. However, the stock price has declined by 6.29% year-to-date. The company's beta is 1.06, indicating that the stock is slightly more volatile than the market.

Investment Thesis

Daiichi Sankyo has shown strong financial performance with increasing revenues and net income. The company operates in a growing industry and has a strong product portfolio. However, the company's high valuation ratios indicate that the stock may be overvalued.

Catalysts

The company's future performance could be influenced by various factors such as new product launches, regulatory approvals, and strategic partnerships.

Risk

Investing in Daiichi Sankyo involves risks such as market risk, regulatory risk, and competition risk. The company's high valuation ratios also indicate a risk of overvaluation.

Investment Thesis

In conclusion, Daiichi Sankyo presents a mixed investment opportunity. The company has strong financial performance and operates in a growing industry. However, the company's high valuation ratios indicate that the stock may be overvalued. Investors should carefully consider these factors before making an investment decision.